Vertex Pharmaceuticals Incorporated
VRTX · Healthcare · Biotechnology
Updated 24 min ago · data delayed ≥15 min
IconicScore
ProprietaryRanked #128 of 500 by Iconic Score · #13 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.
Get the free morning email
The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →
Price performance
Export history · AnalystThis insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.
Upgrade to AnalystThis is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.
Upgrade to EnterpriseIconic Profile
Vertex Pharmaceuticals Inc. (VRTX) is a leading biotechnology company focused on developing transformative therapies for serious diseases, particularly in the areas of cystic fibrosis and sickle cell disease. With a market capitalization of $122.4 billion, Vertex has established a strong position in the healthcare sector through its innovative drug portfolio, including groundbreaking treatments that address the underlying causes of genetic disorders. The company's commitment to research and development, coupled with strategic partnerships, enables it to maintain a competitive edge in the rapidly evolving biotechnology landscape. Vertex's advancements not only improve patient outcomes but also contribute significantly to the broader healthcare ecosystem, making it a key player in the ongoing pursuit of novel therapies for unmet medical needs.
IconicOracleAI™ Brief
Vertex Pharmaceuticals Inc (VRTX) currently holds an Iconic Score of 59, reflecting a moderate brand presence in the market. The company’s recent advancements in drug development and the appointment of Daniel Brennan to its Board of Directors have contributed to increased visibility and positive sentiment. Additionally, headlines discussing its competitive positioning against peers like AbbVie and its recent stock performance suggest a growing interest in the company’s potential within the healthcare sector.
AI-generated explanation of current score drivers. Not investment advice.
Enterprise tier: claim your logo to manage how your brand is represented.